AssetMark’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $2.18M | Sell |
15,392
-1,022
| -6% | -$164K | ﹤0.01% | 927 |
|
|
2026
Q2 | $2.77M | Sell |
16,414
-863
| -5% | -$128K | ﹤0.01% | 878 |
|
|
2026
Q1 | $2.28M | Sell |
17,277
-2,044
| -11% | -$271K | ﹤0.01% | 857 |
|
|
2025
Q4 | $2.74M | Sell |
19,321
-915
| -5% | -$133K | 0.01% | 781 |
|
|
2025
Q3 | $2.84M | Sell |
20,236
-765
| -4% | -$104K | 0.01% | 738 |
|
|
2025
Q2 | $2.64M | Buy |
21,001
+2,045
| +11% | +$235K | 0.01% | 714 |
|
|
2025
Q1 | $2.1M | Sell |
18,956
-958
| -5% | -$121K | 0.01% | 709 |
|
|
2024
Q4 | $2.72M | Buy |
19,914
+1,591
| +9% | +$197K | 0.01% | 641 |
|
|
2024
Q3 | $2.11M | Buy |
18,323
+1,753
| +11% | +$240K | 0.01% | 642 |
|
|
2024
Q2 | $2.28M | Buy |
16,570
+4,460
| +37% | +$612K | 0.01% | 580 |
|
|
2024
Q1 | $1.67M | Sell |
12,110
-24,845
| -67% | -$3.39M | 0.01% | 619 |
|
|
2023
Q4 | $4.87M | Buy |
36,955
+8,678
| +31% | +$999K | 0.02% | 376 |
|
|
2023
Q3 | $3.18M | Buy |
28,277
+4,350
| +18% | +$458K | 0.01% | 424 |
|
|
2023
Q2 | $2.26M | Buy |
23,927
+4,151
| +21% | +$406K | 0.01% | 455 |
|
|
2023
Q1 | $2M | Buy |
19,776
+1,903
| +11% | +$198K | 0.01% | 451 |
|
|
2022
Q4 | $2.13M | Buy |
17,873
+1,471
| +9% | +$172K | 0.01% | 423 |
|
|
2022
Q3 | $1.74M | Buy |
16,402
+2,929
| +22% | +$297K | 0.01% | 407 |
|
|
2022
Q2 | $1.31M | Buy |
13,473
+4,317
| +47% | +$398K | 0.01% | 435 |
|
|
2022
Q1 | $858K | Buy |
9,156
+4,093
| +81% | +$347K | ﹤0.01% | 502 |
|
|
2021
Q4 | $431K | Buy |
5,063
+3,585
| +243% | +$330K | ﹤0.01% | 568 |
|
|
2021
Q3 | $142K | Buy |
+1,478
| New | +$140K | ﹤0.01% | 612 |
|
|
2019
Q3 | – | Sell |
-12
| Closed | -$1K | – | 1382 |
|
|
2019
Q2 | $1K | Buy |
12
+2
| +20% | +$164 | ﹤0.01% | 1252 |
|
|
2019
Q1 | $1K | Sell |
10
-18
| -64% | -$1.5K | ﹤0.01% | 1261 |
|
|
2018
Q4 | $2K | Buy |
+28
| New | +$2.68K | ﹤0.01% | 1224 |
|
|
2018
Q1 | – | Sell |
-20
| Closed | -$2K | – | 1777 |
|
|
2017
Q4 | $2K | Buy |
20
+15
| +300% | +$1.02K | ﹤0.01% | 1463 |
|
|
2017
Q3 | $0 | Buy |
+5
| New | +$264 | ﹤0.01% | 1568 |
|
|
2016
Q1 | – | Sell |
-15
| Closed | -$1K | – | 1336 |
|
|
2015
Q4 | $1K | Buy |
+15
| New | +$762 | ﹤0.01% | 1233 |
|
Other funds holding NBIX
AssetMark's NBIX Position: Q3 2026 in Review
AssetMark reduced its Neurocrine Biosciences (NBIX) stake by 6.2% in Q3 2026, selling an estimated $164K and leaving 15,392 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #927.
AssetMark first reported a position in NBIX in Q4 2015 and has held it in 27 quarters since. The position peaked at $4.87M in Q4 2023. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- AssetMark held 15,392 shares of Neurocrine Biosciences worth $2.18M as of Q3 2026.
- AssetMark sold 1,022 Neurocrine Biosciences shares in Q3 2026, an estimated $164K.
- Neurocrine Biosciences made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #927 holding.
- AssetMark first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 27 quarters since.
- AssetMark's Neurocrine Biosciences position peaked at $4.87M in Q4 2023.
- 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.